ライフサイエンスコーパス: eosinophilia

1 ted AIH and the presence of peripheral blood eosinophilia.

2 l21r(-/-) mice restored T(H)2 generation and eosinophilia.

3 oids to manage severe asthma associated with eosinophilia.

4 subjects with elevated serum IgE and airway eosinophilia.

5 ce, PM2.5 + OVA exacerbated OVA-related lung eosinophilia.

6 ng candidate for exacerbation of murine lung eosinophilia.

7 4 (IL-4) production, IL-5 transcription, and eosinophilia.

8 racterized by airway hyperresponsiveness and eosinophilia.

9 r-old man with jaundice and peripheral blood eosinophilia.

10 the genetic basis of myeloid neoplasms with eosinophilia.

11 on, agmatine positively correlated with lung eosinophilia.

12 l-replicated asthma gene and associates with eosinophilia.

13 d sensitization, airway hyperreactivity, and eosinophilia.

14 tients with severe, uncontrolled asthma with eosinophilia.

15 roid-responsive symptoms, but without tissue eosinophilia.

16 ed by EDN as separators of high vs low blood eosinophilia.

17 ring effects and attenuates blood and sputum eosinophilia.

18 ILCs, can both effectively reduce intestinal eosinophilia.

19 818, had no significant effect on esophageal eosinophilia.

20 icantly inhibited airway hyperreactivity and eosinophilia.

21 in mice that recovered from allergic airway eosinophilia.

22 severity and lung function and module 2 with eosinophilia.

23 osteroid medications, and presence of airway eosinophilia.

24 4 of 20 patients (20%) developed peripheral eosinophilia.

25 otype control antibody, as well as decreased eosinophilia.

26 ies for patients with significant esophageal eosinophilia.

27 IL-5 is a major therapeutic target to reduce eosinophilia.

28 velopment of papain- or IL-33-induced airway eosinophilia.

29 rotease or IL-33-mediated innate-type airway eosinophilia.

30 eight loss and no sign of histopathology and eosinophilia.

31 as associated with a higher hazard of having eosinophilia.

32 e limited to patients with N-ERD with airway eosinophilia.

33 pump inhibitors in patients with esophageal eosinophilia.

34 ted ILC2s in mediating RSV-triggered AHR and eosinophilia.

35 e-phase responses, elevated IgE, eczema, and eosinophilia.

36 inflammation are associated with submucosal eosinophilia.

37 ociated with long-term control of esophageal eosinophilia.

38 R, consistent with the clinical phenotype of eosinophilia.

39 reased efficacy in patients with IL-5-driven eosinophilia.

40 ncluding airway hyperresponsiveness and lung eosinophilia.

41 lung function but had only modest effects on eosinophilia.

42 We also measured peripheral eosinophilia, 4 different eosinophil granule proteins, a

43 e, with infiltrating leukocytes and a marked eosinophilia (49%).

44 Of 263 patients with esophageal eosinophilia, a total of 179 fulfilled the diagnostic cr

45 ther study on the basis of inducing a robust eosinophilia accompanied by degranulation.

46 lete absence of bronchoalveolar lavage fluid eosinophilia, accompanied with significant reduction in

47 MCTR1 and MCTR3 inhibited lung eosinophilia after house dust mite-induced inflammation.

48 ncluding humoral response, airway and tissue eosinophilia, AHR, and TH2 and TH17 pulmonary profiles.

49 levels had inverse correlations with sputum eosinophilia, airway obstruction, and number of hospital

50 2 cell responses, and related events such as eosinophilia, alternative macrophage activation, and imm

51 After exclusion of secondary causes of eosinophilia, an idiopathic hypereosinophilic syndrome (

52 less severe symptoms and more frequently had eosinophilia and a family history of asthma.

53 d by HMW agents showed higher baseline blood eosinophilia and a greater postchallenge increase in fra

54 nstrate a pathogenic role for IL-33-mediated eosinophilia and activation of Th2 immunity in chronic i

55 obial composition was associated with airway eosinophilia and AHR to mannitol but not airway neutroph

56 murine models lacking T and B cells induces eosinophilia and airway hyper-reactivity (AHR), which ar

57 pious amounts of IL-5 and IL-13, which cause eosinophilia and airway hyperreactivity (AHR), a cardina

58 thma approach with assessing the presence of eosinophilia and allergy provides a way for more precise

59 isolone may lead to a prompt amelioration of eosinophilia and associated symptoms.

60 cific overexpression of miR-1 reduced airway eosinophilia and asthma phenotypes in murine models and

61 etermine whether CCL26 levels correlate with eosinophilia and asthma severity.

62 L33 as an epithelial susceptibility gene for eosinophilia and asthma, provide mechanistic insight, an

63 e of relevance for optimal control of airway eosinophilia and asthma.

64 a-challenged TrkA-KI mice markedly inhibited eosinophilia and attenuated various features of AAI.

65 nosed on the basis of bronchoalveolar lavage eosinophilia and blood findings.

66 onse to C. neoformans by promoting pulmonary eosinophilia and by inhibiting the activation and antifu

67 inicopathologic disorder with marked gastric eosinophilia and clinical symptoms.

68 minant process that drives persistent airway eosinophilia and corticosteroid requirement in severe as

69 irb(-/-) mice displayed increased esophageal eosinophilia and EoE pathology, including epithelial cel

70 SOT patients, strongyloidiasis triggers both eosinophilia and eosinophil activation, the latter being

71 expression of IL-3 receptors, whereas airway eosinophilia and eosinophil peroxidase deposition were b

72 highlights advances in our understanding of eosinophilia and eosinophilic disorders (excluding asthm

73 c interleukin-5 (IL-5)-dependent increase in eosinophilia and evidence of eosinophil activation.

74 Endogenously generated cysLTs induced eosinophilia and expanded group 2 innate lymphoid cells

75 tly available inflammatory biomarkers sputum eosinophilia and fractional exhaled nitric oxide levels,

76 bust relationship was observed between blood eosinophilia and IL-5, IL-13, and eosinophil-derived neu

77 easonal allergic rhinitis resulted in tissue eosinophilia and increases in IL-5 but no structural cha

78 c IgG1 and total IgE in serum, and increased eosinophilia and interleukin-5 in bronchoalveolar lavage

79 de of Ccl24 prevented the exaggerated airway eosinophilia and lung inflammation in mice given HDM-pul

80 ry disease (AERD) is characterized by tissue eosinophilia and mast cell activation, including abundan

81 lymphoid cells (ILC2s), which promote tissue eosinophilia and mast cell responses, undergo chemotaxis

82 of allergic airway disease, including airway eosinophilia and methacholine hyper-responsiveness.

83 cells to generate PGD2 and facilitate tissue eosinophilia and nasal polyposis in patients with AERD.

84 ental RV infection induces bronchial mucosal eosinophilia and neutrophilia only in patients with COPD

85 d asthma phenotype characterized by elevated eosinophilia and neutrophilia, tissue inflammation, mucu

86 , NOS) is assigned to patients with MPN with eosinophilia and nonspecific cytogenetic/molecular abnor

87 end organ manifestations attributable to the eosinophilia and not otherwise explained in the clinical

88 th CARMA3-deficient AECs have reduced airway eosinophilia and proinflammatory cytokine production in

89 ) category, "Myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGF

90 2 high inflammation cluster characterized by eosinophilia and recurrent exacerbations, as well as Typ

91 In addition, pIL5 treatment could induce eosinophilia and reduce Pneumocystis burden in CD4-deple

92 Impaired skin eosinophilia and reduced ear swelling was further observ

93 tial therapeutic target to reduce esophageal eosinophilia and remodeling.

94 of clinical treatable traits, such as airway eosinophilia and risk of infection/exacerbation, that ar

95 demographic data and antibiotic exposures on eosinophilia and subsequent HSRs, including documented r

96 equency and predictors of antibiotic-induced eosinophilia and subsequent hypersensitivity reactions (

97 te histamine, to wild-type mice reduced lung eosinophilia and suppressed ex vivo OVA-stimulated cytok

98 tivation is well known in drug reaction with eosinophilia and systemic symptom (DRESS), but such a ph

99 hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DiHS/DRESS) is a pot

100 Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare sev

101 Possible drug rash with eosinophilia and systemic symptoms (DRESS) syndrome case

102 Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a

103 ome (DIHS), also known as drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, is

104 sm in the pathogenesis of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome.

105 pidermal necrolysis (TEN), or drug rash with eosinophilia and systemic symptoms (DRESS), are rarely r

106 hypersensitivity syndrome drug reaction with eosinophilia and systemic symptoms (DRESS), which leads

107 d started in 14/25 with a drug reaction with eosinophilia and systemic symptoms (DRESS).

108 One serious case of drug reaction with eosinophilia and systemic symptoms occurred in the 200 m

109 us) were suspected to trigger drug rash with eosinophilia and systemic symptoms or GVHD.

110 ypersensitivity syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, and Stevens

111 chronic GVHD or unrecognized drug rash with eosinophilia and systemic symptoms, the others recovered

112 Traf4 (-/-) mice resulted in blunted airway eosinophilia and Th2 cytokine production.

113 Local tissue eosinophilia and Th2 cytokines are characteristic featur

114 with attenuation of allergen-induced sputum eosinophilia and with lower levels of tryptase in sputum

115 endent secretion of type 2 cytokines, airway eosinophilia, and airway hyperresponsiveness in juvenile

116 All 4 affected patients had eosinophilia, and both patients with Leu583-Ala586DelIns

117 Plgf dampened AHR, reduced inflammation and eosinophilia, and decreased expression of the Th2 cytoki

118 culating eosinophils, bronchoalveolar lavage eosinophilia, and eosinophil peroxidase deposition in br

119 of ovalbumin-induced airway hyperreactivity, eosinophilia, and goblet cell metaplasia in allergen-sen

120 I-RSV immune mice showed severe weight loss, eosinophilia, and histopathology, and RSV reinfection al

121 cy increased inflammatory cell infiltration, eosinophilia, and IL-5 and IL-13 expression in the lung

122 cells induced marked pulmonary inflammation, eosinophilia, and increased bronchoalveolar lavage fluid

123 nergistic increases in airway Th2 cytokines, eosinophilia, and peribronchial inflammation compared wi

124 presentation of frequent exacerbators, blood eosinophilia, and submucosal infiltration of T cells and

125 asthma and low lung function, high baseline eosinophilia, and the greatest CS responsiveness.

126 Allergen sensitisation, airway eosinophilia, and type 2 inflammation predominate in old

127 perresponsiveness, mucus hyperplasia, airway eosinophilia, and type 2 pulmonary inflammation.

128 This response is typified by massive eosinophilia, and we were able to confirm pyroptosis in

129 Blood eosinophilia appeared to be a useful predictor of airway

130 Pulmonary symptoms with eosinophilia are most common, though 1 case did involve

131 ii) compare its diagnostic value with sputum eosinophilia as gold standard and (iii) validate the mod

132 s the most important distinguisher and blood eosinophilia as second most important identifier in prin

133 ontaneous progressive skin inflammation with eosinophilia, as well as increased levels of thymic stro

134 y for 10 days, a sequence leading to gastric eosinophilia assessed by endoscopy.

135 Fourth, surprisingly, eosinophilia, associated with T helper 2, may be protect

136 First, do patients with eosinophilia-associated diseases have an altered course

137 icance, reclassifying some of these cases as eosinophilia-associated neoplasms.

138 nclusion in the current WHO-defined group of eosinophilia-associated TK fusion-driven neoplasms.

139 IL-13 are reliable biomarkers for the blood eosinophilia asthma phenotype.

140 utrophils and was associated with persistent eosinophilia at 48 hours.

141 y characterized by elevated serum IgE level, eosinophilia, atopy, and immune dysregulation.

142 nts that have been diagnosed with esophageal eosinophilia between 1993 and 2013.

143 In severe asthmatics with persistent airway eosinophilia, blockade of interleukin-5 has significant

144 to SplD led to IL-33 and eotaxin production, eosinophilia, bronchial hyperreactivity, and goblet cell

145 ltr1 blunted LTC4-induced ILC2 expansion and eosinophilia but did not alter IL-33 induction.

146 tly decreased esophageal and bronchoalveolar eosinophilia but only when given as a therapeutic treatm

147 ificantly attenuated allergen-induced sputum eosinophilia by 63 and 61% at 7 hours, respectively, and

148 ase allergens, can induce innate-type airway eosinophilia by activating natural helper (NH) cells, a

149 Esophageal eosinophilia can be proton pump inhibitor (PPI) resistan

150 y, but it is now appreciated that esophageal eosinophilia can respond to proton pump inhibitors.

151 88, in exacerbation of allergen-induced lung eosinophilia caused by urban PM2.5 was investigated.

152 c food antigens, leading to dense esophageal eosinophilia, chronic inflammation, and esophageal fibro

153 re characterized by gastrointestinal mucosal eosinophilia, chronic symptoms, impaired quality of life

154 milar phenotype resulting in enhanced airway eosinophilia compared to WT mice.

155 d SP-A therapy had significantly less tissue eosinophilia compared with mice receiving vehicle.

156 Although drug-induced peripheral eosinophilia complicates antimicrobial therapy, little i

157 misation, we show that a primary tendency to eosinophilia contributes to EGPA susceptibility.

158 The severity of epithelial esophageal eosinophilia correlated with epithelial remodeling (basa

159 p3 (-/-) mice had increased neutrophilia and eosinophilia, correlating with enhanced worm killing but

160 nfections, eczema, bronchiectasis, high IgE, eosinophilia, defective B cell memory, and an impaired a

161 ow limitation in asthma patients with airway eosinophilia despite treatment with high-dose inhaled co

162 Only IL-13 was associated with airway eosinophilia, development of airway hyperresponsiveness,

163 Although most patients with eosinophilia do not have an HSR, eosinophilia increases

164 Patients suffering from 'EoE without eosinophilia' do not fulfill formally the diagnostic cri

165 neous drug-reaction had higher proportion of eosinophilia during treatment, and higher interleukin (I

166 with inflammatory disorders involving marked eosinophilia (e.g. asthma), were particularly elevated i

167 Type 2 inflammation (eosinophilia, eotaxin-2 expression, IL-4/IL-5/IL-13 prod

168 nd assessed for histopathological indices of eosinophilia, epithelial hyperplasia, and angiogenesis b

169 cated in allergic asthma, Th2 activation and eosinophilia (EPX, IL4, IL13) and genes previously assoc

170 Periostin did not identify blood or sputum eosinophilia, even after stratification for total IgE, a

171 nchodilators in patients with COPD and blood eosinophilia, except for those patients with a history o

172 ated for phenotypic traits, sputum and blood eosinophilia, exhaled NO, serum cytokines and chemokines

173 Familial eosinophilia (FE) is a rare autosomal dominant inherited

174 Patients with eosinophilia frequently develop cardiomyopathies.

175 rks of allergic airway disease, such as lung eosinophilia, goblet cell hyperplasia, Ag-specific Th2 r

176 se in which treated mice were protected from eosinophilia, goblet cell hyperplasia, and T(H)2 cell in

177 mation, as characterized by increased airway eosinophilia, goblet cell metaplasia, accumulation of IL

178 allergic airway inflammation with increased eosinophilia, goblet cell metaplasia, and TH2 cytokine p

179 rized by the presence of lifelong peripheral eosinophilia (>1500/muL).

180 6.2% or more (median in patients with sputum eosinophilia, >3%), eosinophils decreased from a median

181 These studies show that pulmonary eosinophilia has dual outcomes: one linked to RSV-induce

182 phagitis (EoE) and extremely high esophageal eosinophilia have a distinct endotype defined by more se

183 She showed peripheral blood eosinophilia, high level of FENO, bronchial hyperrespons

184 , we found that NP-CpG significantly reduced eosinophilia, IgE levels, mucus production and Th2 cytok

185 NP) in Western countries is characterized by eosinophilia, IgE production, and TH2 cytokine expressio

186 ed in a significant diminution of epithelial eosinophilia in addition to basal cell hyperplasia and v

187 rmulation, to reduce symptoms and esophageal eosinophilia in adolescents and adults with EoE.

188 ivates platelets in vitro and induces airway eosinophilia in allergen-sensitized and -challenged mice

189 ediator in resolving tissue and lavage fluid eosinophilia in allergic mouse models.

190 and dose-dependently counteracted acute lung eosinophilia in an experimental animal model.

191 ome is a group of diseases defined by marked eosinophilia in blood or tissue and eosinophil-related c

192 d humanized SP-A2 223K/K mice had persistent eosinophilia in bronchoalveolar lavage fluid compared wi

193 , which assesses the presence of allergy and eosinophilia in each asthmatic patient.

194 are consistent with the hypothesis that the eosinophilia in FE is secondary to dysregulation of IL-5

195 study was to identify the cells driving the eosinophilia in FE.

196 Moreover, the etiology of the eosinophilia in HESs can be primary (myeloid), secondary

197 itized WT mice suppressed the enhancement of eosinophilia in IL-15(-/-) animals to levels observed in

198 airway hyperresponsiveness (AHR) and airway eosinophilia in mice following allergen challenge.

199 ongly potentiates allergen-induced pulmonary eosinophilia in mice through a CysLT(2)R-mediated, plate

200 Helminth infections are accompanied by eosinophilia in parasitized tissues.

201 s in asthmatic patients and sinonasal tissue eosinophilia in patients with CRS.

202 tion by BECs might be involved in persistent eosinophilia in patients with severe asthma despite trea

203 This study established a model of gastric eosinophilia in peanut-sensitized piglets to evaluate th

204 To explore the role of IL-5 driven eosinophilia in post-DEC reactions, 8 adults with confir

205 tivity and specificity for predicting sputum eosinophilia in the 3 weight groups.

206 tional cytokine signals involved in residual eosinophilia in the absence IL-4Ralpha signaling and def

207 V challenge; however, the roles of pulmonary eosinophilia in the antiviral response and in disease pa

208 Histopathological examination revealed eosinophilia in the bronchial secretions and mild nonspe

209 as restricted to a subgroup of patients with eosinophilia in the lower airway.

210 L5-treated mice had increased serum IL-5 and eosinophilia in the lung, as well as reduced Pneumocysti

211 stomach, crypt distortion in the colon, and eosinophilia in the rectosigmoid distinguished the IBD g

212 tosis, suggesting a pathway for ameliorating eosinophilia in the setting of asthma and other eosinoph

213 e for NLRP1 inflammasome activation reducing eosinophilia in this setting.

214 To drive eosinophilia in vivo, Rag1(-/-) mice were treated with a

215 body led to robust depletion of IL-5-induced eosinophilia in vivo.

216 d airway inflammation (both neutrophilia and eosinophilia) in a mouse model of severe allergic asthma

217 ory products and described several causes of eosinophilia including asthma, various skin diseases, he

218 sequent HSR in 64 (30%) of 210 patients with eosinophilia, including rash (n = 32), renal injury (n =

219 tients with eosinophilia do not have an HSR, eosinophilia increases the hazard rate of having rash an

220 The identification of sputum eosinophilia indicating corticosteroid responsiveness in

221 ysiology, including lung function and airway eosinophilia induced by Alternaria.

222 Esophagitis with eosinophilia, inflammation, and fibrosis represent a chr

223 owing challenge there were reduced pulmonary eosinophilia, inflammation, Th2-type cytokine responses,

224 Eosinophilia is a central feature of the host response t

225 Eosinophilia is a common, but not invariable, feature of

226 Eosinophilia is a hallmark of allergic airway inflammati

227 Lung eosinophilia is a hallmark of asthma, and eosinophils ar

228 Airway eosinophilia is a prominent feature of asthma and chroni

229 Eosinophilia is associated with worsening asthma severit

230 T(H)2-cell-driven airway eosinophilia is attenuated by ablation of CD11c-expressi

231 Drug-induced eosinophilia is common with parenteral antibiotics.

232 Local and peripheral eosinophilia is linked to both ILC2 and myeloid IL-33 si

233 ral circulation to the development of airway eosinophilia is not known.

234 an overlap with asthma but the mechanism of eosinophilia is uncertain as, although an increase in sp

235 tory diseases, the role of EBI2 in pulmonary eosinophilia is unknown.

236 me, focused on the hypothesis that pulmonary eosinophilia linked with allergic respiratory disease is

237 Lymphopenia, eosinophilia, low numbers of naive CD8(+) T cells and sw

238 ay allergy, with increased airway and tissue eosinophilia, lung inflammation, and IL-4, IL-5, IL-13,

239 id malignancies in patients with unexplained eosinophilia may reveal additional cases of Leu583-Ala58

240 rs, such as allergic sensitization and blood eosinophilia, might be important predictors of response

241 f the DNA-PK inhibitor NU7441 reduced airway eosinophilia, mucus hypersecretion, airway hyperresponsi

242 IL-4), IL-5, and IL-13, which promote airway eosinophilia, mucus overproduction, bronchial hyperrespo

243 or evaluation of airway hyperresponsiveness, eosinophilia, mucus production, inflammatory gene expres

244 ntation was dyspnea (59.4%), with peripheral eosinophilia observed in 75.9%.

245 disorders characterized by peripheral blood eosinophilia of 1.5 x 10(9)/L or higher and evidence of

246 large subgroup of asthmatics have associated eosinophilia, often accompanied by inflammation associat

247 tient with an angiolymphoid hyperplasia with eosinophilia or Kimura disease.

248 mphocyte subsets to produce this dichotomous eosinophilia or neutrophilia.

249 cytic asthma, which occurs in the absence of eosinophilia or neutrophilia.

250 On the contrary, eosinophilia (OR, 1.6; P = 0.0002), lymphocytosis (OR, 1

251 rcellular spaces; P < .0001), lamina propria eosinophilia (P < .0001), and fibrosis (P < .0001).

252 ) locations, and associated with bone marrow eosinophilia (P < .01).

253 axin, and IL-8 identified two separate blood eosinophilia patient clusters linked to asthma severity.

254 of intranasal IRL201104 against OVA-induced eosinophilia persisted for up to 20 days post-treatment.

255 ough reslizumab was able to blunt peripheral eosinophilia post-DEC treatment in subjects with loiasis

256 ed with allergic type-2 immune responses and eosinophilia post-ivermectin treatment.

257 phagitis (EoE) and PPI-responsive esophageal eosinophilia (PPI-REE), respectively.

258 Peripheral eosinophilia predicted resolution.

259 Further, eosinophilia, protein level of lung IL-4, IL-5, and IL-1

260 doscopic severity correlated with esophageal eosinophilia (r = 0.73, P < .001).

261 (H)2 cells were highly correlated with blood eosinophilia (r = 0.78-0.98) and were present in 30- to

262 er, abdominal pain, and diarrhea, along with eosinophilia ranging from 0.9 x 109/L to 6.1 x 109/L.

263 h proton pump inhibitor-resistant esophageal eosinophilia received intravenous QAX576 (6 mg/kg) or pl

264 ameliorated allergen-induced airway and lung eosinophilia, reduced type 2 cytokine levels in bronchia

265 rway hyperreactivity (AHR), inflammation and eosinophilia remained to be clarified.

266 ergen-induced bronchoconstriction and airway eosinophilia result in increased cough reflex sensitivit

267 skin accompanied by notable peripheral blood eosinophilia, sinusitis, and pulmonary nodules on radiog

268 These mice exhibit lung eosinophilia; smooth muscle cell, collagen, and goblet c

269 oms, paraesthesia or hyperaesthesia, and CSF eosinophilia so that treatment can be started early, whi

270 sphingolipidomics were performed, and airway eosinophilia, T(H)2 cytokine production, immunoglobulin

271 clusters (T2, T3, and T4) had higher sputum eosinophilia than cluster T1, with no differences in spu

272 p1 elicits helper T (Th) cell-dependent lung eosinophilia that is initiated by the rapid response of

273 -11 and polyclonal B5, inhibited AHR, airway eosinophilia, the increase of cytokines in the lung tiss

274 Conventional EoE, with its prominent eosinophilia, therefore appears to be only one phenotype

275 cins by which their glycans can control lung eosinophilia through engagement of Siglec-F.

276 allergen and compared the effects on airway eosinophilia, type 2 cytokine levels, goblet cell metapl

277 nflammation exemplified by diminished airway eosinophilia, type 2 cytokine production and mucus secre

278 anism, which is reliant on IL-5-induced lung eosinophilia, ultimately limiting the metabolic fitness

279 ian cells has been shown to induce pulmonary eosinophilia upon RSV infection in a mouse model.

280 onide did not reduce allergen-induced sputum eosinophilia versus placebo.

281 mong children with "Difficult asthma"; blood eosinophilia was a significant feature of "Difficult," "

282 n CCR3 within IL-4Ralpha(-/-) mice, residual eosinophilia was ablated, and susceptibility to chronic

283 An associated residual eosinophilia was apparent in infected IL-4Ralpha(-/-) mi

284 Also, in IBS patients, rectosigmoid eosinophilia was associated with higher anxiety scores a

285 High sputum eosinophilia was in line with higher pro-inflammatory LT

286 Lower airway eosinophilia was more frequent in N-ERD (54.5%) than in

287 No significant effect on eosinophilia was observed when NCC 2287 was given as a p

288 Tissue eosinophilia was quantified by using Congo red and anti-

289 Bone marrow and tissue eosinophilia were also suppressed with benralizumab ther

290 epressed consciousness, and peripheral blood eosinophilia were associated with PCR positivity.

291 markers that identify the phenotype of blood eosinophilia were evaluated in adult asthmatics, and the

292 LC2 axis in RSV-induced AHR inflammation and eosinophilia were evaluated in the IL-33-deficient and Y

293 EBI2 ligands and pulmonary eosinophilia were measured in the bronchoalveolar lavage

294 0 years with dysphagia and active esophageal eosinophilia were randomized to receive either BOS 2 mg

295 Patients with eosinophilia were significantly more likely to have rash

296 with acute myeloid leukemia subtype M4 with eosinophilia, which generates a CBFB-MYH11 fusion gene.

297 l phenylalanine was found to identify sputum eosinophilia with 90.5% sensitivity and 91.5% specificit

298 an therapy duration, 41 days), 210 (25%) had eosinophilia, with median peak absolute eosinophil count

299 nse to HDM, reducing IL-13 levels and airway eosinophilia without affecting IgE levels or airway hype

300 m 5 years and 10 months of age and developed eosinophilia without diarrhea or bloody stool.